Display options
Cite
Ravingerová T, Adameová A, Matejíková J, et al. Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart. Exp Clin Cardiol. 2010;15(4):68-76
Ravingerová, T., Adameová, A., Matejíková, J., Kelly, T., Nemčeková, M., Kucharská, J., Pecháňová, O., & Lazou, A. (2010). Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart. Experimental and clinical cardiology, 15(4), 68-76.
Ravingerová, T, et al. "Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart." Experimental and clinical cardiology vol. 15,4 (2010): 68-76.
Ravingerová T, Adameová A, Matejíková J, Kelly T, Nemčeková M, Kucharská J, Pecháňová O, Lazou A. Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart. Exp Clin Cardiol. 2010;15(4):68-76. PMID: 21264077; PMCID: PMC3016064.
Copy Download .nbib Format: NLM
Share it on

Exp Clin Cardiol. 2010;15(4):68-76.

Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart.

Experimental and clinical cardiology

T Ravingerová, A Adameová, J Matejíková, T Kelly, M Nemčeková, J Kucharská, O Pecháňová, A Lazou

Affiliations

  1. Institute for Heart Research, Slovak Academy of Sciences and Centre of Excellence for Cardiovascular Research SAS;

PMID: 21264077 PMCID: PMC3016064

Abstract

Although hyperglycemia is one factor that determines the outcome of myocardial ischemic insult, it is still not clear whether it is causally related to decreased ischemic tolerance in diabetic patients. In contrast to clinical and epidemiological studies demonstrating a higher risk of cardiovascular disorders in diabetic patients, experimental data are not unequivocal and suggest that, aside from higher myocardial vulnerability, diabetes mellitus may be associated with the triggering of adaptive processes leading to paradoxically lower susceptibility to ischemia. It has been proposed that this phenomenon shares some molecular pathways with short-term preconditioning and other forms of endogenous protection against ischemia/reperfusion injury in the nondiseased heart. The present article reviews some controversial findings of enhanced resistance to ischemia in the diabetic heart that stem from experimental studies in different models of myocardial ischemia/reperfusion injury. Specifically, it addresses the issue of potential mechanisms of increased resistance to ischemia in an experimental model of streptozotocin-induced diabetes, particularly with respect to the role of reactive oxygen species, hyperglycemia as one of the stress factors, and cell-signalling mechanisms mediated by 'prosurvival' cascades of protein kinases in relation to the mechanisms of classical ischemic preconditioning. Finally, mechanisms involved in the suppression of protection in the diabetic myocardium including the effect of concomitant pathology, such as hypercholesterolemia, are discussed.

Keywords: Adaptation; Cell signalling; Diabetic heart; Myocardial ischemia

References

  1. Cardiovasc Res. 1993 Apr;27(4):644-51 - PubMed
  2. Mol Cell Biochem. 2000 Jul;210(1-2):143-51 - PubMed
  3. Gen Physiol Biophys. 2005 Dec;24(4):411-26 - PubMed
  4. Physiol Res. 2009;58(3):443-447 - PubMed
  5. Mol Cell Biochem. 1992 Feb 12;109(2):173-9 - PubMed
  6. Can J Physiol Pharmacol. 2009 Dec;87(12):1028-36 - PubMed
  7. J Cardiovasc Electrophysiol. 1995 Nov;6(11):1039-62 - PubMed
  8. J Pharmacol Exp Ther. 2006 Jan;316(1):154-61 - PubMed
  9. Clin Sci (Lond). 1996 Oct;91(4):441-8 - PubMed
  10. J Mol Cell Cardiol. 1998 Sep;30(9):1869-75 - PubMed
  11. Cardiovasc Res. 1990 Nov;24(11):873-8 - PubMed
  12. Physiol Res. 2008;57 Suppl 2:S55-S60 - PubMed
  13. Life Sci. 1999;65(18-19):1999-2001 - PubMed
  14. J Biochem Mol Toxicol. 2003;17(1):24-38 - PubMed
  15. J Physiol. 1995 Nov 1;488 ( Pt 3):673-88 - PubMed
  16. Am J Physiol Heart Circ Physiol. 2000 Jun;278(6):H1948-54 - PubMed
  17. Diabetes Res Clin Pract. 1996 Jul;31 Suppl:S113-22 - PubMed
  18. Exp Mol Pathol. 2004 Feb;76(1):57-65 - PubMed
  19. Annu Rev Physiol. 2007;69:51-67 - PubMed
  20. Bratisl Lek Listy. 2001;102(11):515-9 - PubMed
  21. Cardiovasc Res. 1997 Apr;34(1):113-20 - PubMed
  22. Ann N Y Acad Sci. 2002 Jun;967:463-8 - PubMed
  23. Rev Port Cardiol. 1996 Oct;15(10):703-8 - PubMed
  24. Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H224-30 - PubMed
  25. Basic Res Cardiol. 2001 Apr;96(2):160-8 - PubMed
  26. Diabetes. 1994 Jun;43(6):831-5 - PubMed
  27. Mol Cell Biochem. 2003 Jul;249(1-2):167-74 - PubMed
  28. Mol Cell Biochem. 1996 May 10;158(1):43-51 - PubMed
  29. Diabetologia. 2006 Mar;49(3):598-606 - PubMed
  30. J Mol Cell Cardiol. 1995 Sep;27(9):1883-94 - PubMed
  31. Eur J Pharmacol. 2007 Dec 8;576(1-3):114-21 - PubMed
  32. Circ J. 2003 Nov;67(11):955-61 - PubMed
  33. J Thorac Cardiovasc Surg. 1996 Sep;112(3):778-86 - PubMed
  34. Circ Res. 1988 May;62(5):931-40 - PubMed
  35. Circ Res. 2004 Sep 17;95(6):568-78 - PubMed
  36. Circ Res. 1997 Dec;81(6):1027-33 - PubMed
  37. Mol Cell Biochem. 2007 Jan;295(1-2):129-36 - PubMed
  38. Am J Physiol. 1990 Jan;258(1 Pt 2):H255-61 - PubMed
  39. Nature. 1983 Sep 8-14;305(5930):147-8 - PubMed
  40. Diabetes Res Clin Pract. 1996 Jul;31 Suppl:S105-12 - PubMed
  41. Neurosci Behav Physiol. 2007 Jun;37(5):489-93 - PubMed
  42. Cardiovasc Res. 2006 May 1;70(2):240-53 - PubMed
  43. Circulation. 1993 Mar;87(3):881-92 - PubMed
  44. Diabetes. 2005 Aug;54(8):2360-4 - PubMed
  45. Acta Physiol (Oxf). 2007 Nov;191(3):171-88 - PubMed
  46. Cardiovasc Res. 1997 Apr;34(1):104-12 - PubMed
  47. Eur J Pharmacol. 2005 May 16;515(1-3):142-9 - PubMed
  48. Life Sci. 1985 Aug 12;37(6):547-51 - PubMed
  49. Jpn J Physiol. 1999 Oct;49(5):409-15 - PubMed
  50. Cardiovasc Res. 2004 Feb 15;61(3):512-21 - PubMed
  51. Circulation. 1979 Jan;59(1):8-13 - PubMed
  52. Circulation. 1993 Sep;88(3):1273-8 - PubMed
  53. J Mol Cell Cardiol. 1992 Apr;24(4):411-21 - PubMed
  54. Clin Exp Pharmacol Physiol. 2006 Oct;33(10):910-6 - PubMed
  55. Cardiovasc Res. 2006 Feb 1;69(2):450-8 - PubMed
  56. Physiol Res. 2009;58(1):9-19 - PubMed
  57. J Mol Cell Cardiol. 1995 Jan;27(1):169-79 - PubMed
  58. Adv Cardiol. 2008;45:154-170 - PubMed
  59. Cardiovasc Res. 1996 Apr;31(4):526-36 - PubMed
  60. Mol Cell Biochem. 2003 Jul;249(1-2):59-65 - PubMed
  61. Cardiovasc Res. 1998 Nov;40(2):239-47 - PubMed
  62. Eur J Heart Fail. 2010 Jul;12(7):659-67 - PubMed
  63. Cardiovasc Res. 1993 Nov;27(11):1908-12 - PubMed
  64. J Am Coll Cardiol. 1998 Apr;31(5):950-6 - PubMed
  65. Mol Cell Biochem. 1997 Nov;176(1-2):191-8 - PubMed
  66. Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):415-27 - PubMed
  67. Cell Mol Biol (Noisy-le-grand). 1992 Nov;38(7):739-49 - PubMed
  68. Heart Fail Rev. 2007 Dec;12(3-4):181-8 - PubMed
  69. Circ Res. 1991 Apr;68(4):1127-37 - PubMed
  70. Circulation. 1994 Aug;90(2):700-5 - PubMed
  71. Biochim Biophys Acta. 2007 Aug;1767(8):1007-31 - PubMed
  72. Can J Physiol Pharmacol. 2008 Apr;86(4):166-72 - PubMed
  73. Circ Res. 1992 Feb;70(2):223-33 - PubMed
  74. Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1343-50 - PubMed
  75. Adv Exp Med Biol. 2001;498:213-20 - PubMed

Publication Types